Allen’s formal training is in chemistry, molecular genetics, and neurobiology. After more than 25 years of professional experience in hematology, immunology, and oncology, he’s worked at Exelixis, Genentech, Juno Therapeutics, NGM Bio, Vera Therapeutics, and now serves as CSO at Adanate. In work that spans both biologic and small molecule platforms, he has advanced programs that include small molecule inhibitors, conventional antibody therapeutics, antibody-drug conjugates, and T-cell recruiting. Allen has played a key role in the ideation, discovery, and development of a dozen candidates that progressed to clinical development including two that achieved FDA approvals, polatuzumab vedotin and mosunetuzumab.